RCUS COO exercised options and sold 50,292 shares under 10b5-1

Rhea-AI Filing Summary

Insider transactions by Arcus Biosciences (RCUS): The company's Chief Operating Officer exercised stock options and sold a total of 50,292 shares across two dates, 10/06/2025 and 10/08/2025. The exercises used options with a $1.2276 exercise price, adding 50,292 underlying shares to the reporting pool. Sales were executed at weighted-average prices of $14.5441 and $15.0458, and the filings state these transactions were made pursuant to a Rule 10b5-1 trading plan. Following the transactions the reporting person beneficially owned 214,232 shares, which includes 863 shares bought via the employee stock purchase plan on 05/30/2025. The options exercised were fully vested and exercisable, with expiration dates noted as 03/14/2027.

Positive

• Transactions executed under a Rule 10b5-1 plan, indicating a pre-established trading arrangement
• Options were fully vested and exercisable, so exercises did not accelerate vesting

Negative

• Total of 50,292 shares sold, reducing direct beneficial ownership to 214,232 shares
• Sales occurred at market prices (weighted averages $14.5441 and $15.0458), which may be viewed unfavorably by some investors

Insights

Corporate Governance Expert

TL;DR: Officer exercised vested options then sold shares under a Rule 10b5-1 plan, reducing direct holdings to 214,232 shares.

Mechanics: The reporting person exercised stock options with a $1.2276 exercise price on 10/06/2025 and 10/08/2025

The exercised shares (total 50,292) were immediately sold at weighted-average prices of $14.5441 and $15.0458, with the filings stating the transactions were executed under a Rule 10b5-1 trading plan. The options are fully vested and expire on 03/14/2027.

Dependencies and near-term items: Because the sale was under a pre-established 10b5-1 plan, timing was planned rather than ad hoc; investors might monitor any future plan disclosures or subsequent Form 4 filings for changes in ownership or additional plan-based trades within the next 12–18 months.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jarrett Jennifer

(Last) (First) (Middle)

C/O ARCUS BIOSCIENCES, INC.

3928 POINT EDEN WAY

(Street)

HAYWARD CA 94545

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arcus Biosciences, Inc. [ RCUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/06/2025		M		12,500(1)	A	$1.2276	226,732(2)	D
Common Stock	10/06/2025		S		12,500(1)	D	$14.5441(3)	214,232(2)	D
Common Stock	10/08/2025		M		37,792(1)	A	$1.2276	252,024(2)	D
Common Stock	10/08/2025		S		37,792(1)	D	$15.0458(4)	214,232(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.2276	10/06/2025		M(1)			12,500	(5)	03/14/2027	Common Stock	12,500	$0	168,666	D
Stock Option (Right to Buy)	$1.2276	10/08/2025		M(1)			37,792	(5)	03/14/2027	Common Stock	37,792	$0	130,874	D

Explanation of Responses:

1. The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

2. Includes 863 shares purchased on 5/30/2025 through the Company's Employee Stock Purchase Plan.

3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.40 to $14.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

5. The option is fully vested and currently exercisable.

Remarks:

	/s/ Carolyn Tang, Attorney-in-Fact	10/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Arcus (RCUS) insider do on 10/06/2025 and 10/08/2025?

The Chief Operating Officer exercised options and sold a total of 50,292 shares on 10/06/2025 and 10/08/2025, under a Rule 10b5-1 plan.

At what prices were the RCUS shares sold?

Sales were executed at weighted-average prices of $14.5441 on 10/06/2025 and $15.0458 on 10/08/2025.

How many shares does the reporting person own after these transactions?

Following the reported transactions, the reporting person beneficially owned 214,232 shares.

Were the option exercises and sales part of a planned trading program?

Yes, the Form states the option exercises and sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

What was the exercise price and are the options still valid?

The exercised options had an exercise price of $1.2276 and are fully vested and exercisable, with expiration on 03/14/2027.